A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy
Brachytherapy · 2023
DOI: 10.1016/j.brachy.2023.06.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2023. Verfasst von Charles T Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: charles.lee@fccc.edu. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
PURPOSE: We hypothesize rectal hydrogel spacer (RHS) improves rectal dosimetry in patients undergoing salvage high-dose-rate brachytherapy (HDR-BT) for intact, recurrent prostate cancer (PC). METHODS AND MATERIALS: A prospectively collected institutional database was queried for recurrent PC patients treated with salvage HDR-BT from September 2015 to November 2021. Patients were offered RHS beginning June 2019. Dosimetric variables were compared between RHS and no-RHS groups for the average of two fractions using Wilcoxon rank-sum tests. Primary outcomes were rectal volume receiving 75% of prescription dose (V75%) and prostate volume receiving 100% of prescription dose (V100%). Generalized estimating equation (GEE) model was used to evaluate the association between other planning variables and rectal V75%. RESULTS: Forty-one PC patients received salvage HDR-BT, of whom 20 had RHS. All patients received 2400cGy in 2 fractions. Median RHS volume was 6.2cm3 (Standard deviation [SD]: ± 3.5cm3). Median follow-up was 4 months and 17 months in the RHS and no-RHS groups, respectively. Median rectal V75% with and without RHS were 0.0cm3 (IQR: 0.0-0.0cm3) and 0.06cm3 (IQR: 0.0-0.14cm3), respectively (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: charles.lee@fccc.edu.
- Doctor of Osteopathic Medicine Program, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.
- Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA.
- Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Lee, C. T., Koleoso, O., Deng, M., Veltchev, I., Lin, T., Hallman, M. A., Horwitz, E. M., & Wong, J. K. (2023). A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy. Brachytherapy. https://doi.org/10.1016/j.brachy.2023.06.003
Vancouver
Lee CT, Koleoso O, Deng M, Veltchev I, Lin T, Hallman MA, et al. A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy. Brachytherapy. 2023. doi:10.1016/j.brachy.2023.06.003
BibTeX
@article{Lee2023,
author = {Lee, Charles T and Koleoso, Olufela and Deng, Mengying and Veltchev, Iavor and Lin, Teh and Hallman, Mark A and Horwitz, Eric M and Wong, J Karen},
title = {A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy},
journal = {Brachytherapy},
year = {2023},
doi = {10.1016/j.brachy.2023.06.003}
}
EUVIMED